The study sponsored by MNL Group and ANKLAM Extract consisted of 74 participants who had eye dryness, eye fatigue and were exposed to more than 4 hours of visual display terminals (VDT) at work daily. Test subjects took a 60 mg capsule once a day for four weeks. Those who took MaquiBright and not the placebo had alleviated eye dryness and showed promising results for the relief of eye fatigue.
“This study demonstrates benefits of dry eye reduction with participants receiving dosage as a supplement,” said Humberto Zuckerman, vice president of marketing and sales at MNL Group. “People now have an easier choice to combat dry eye. They can simply take one capsule of MaquiBright a day to complement the usage of eye drops multiple times a day.”
The 2013 U.S. National Health and Wellness Survey showed 16.4 million people in the U.S. suffer from dry eyes symptoms. The global revenues of manufacturers producing dry eye treatment products is expected to grow from $4.6 billion in 2018 to $6.2 billion by 2023.
“The results of this study solidify the eye health benefits associated with MaquiBright,” said Anthony Palmieri, senior director of global business development at Charles Bowman and Company. “Companies looking to expand product lines into the eye health category can rest assured the science matches the benefits.”